Читать книгу Interventional Cardiology - Группа авторов - Страница 342

The use of ECMO for cardiogenic shock has evolved significant during the past decade. Compared with other support devices, ECMO is able to provide higher blood flow rates, oxygenation and ability to support both the left‐ as well as the right ventricle. Important advances include a compact ECMO device (Cardiohelp®, Maquet, Rastatt, Germany) allowing for out‐of‐hospital or bedside ECMO insertion. French physicians have pioneered pre‐hospital extracorporeal cardiopulmonary resuscitation with encouraging survival rates (ECPR) [31]. Several randomized controlled trials investigating ECMO in cardiogenic shock are currently ongoing including the ECMO‐CS (Extra Corporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) [32], ANCHOR (assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock, NCT 04184635), ECLS‐SHOCK (Extracorporeal Life Support in Cardiogenic Shock, NCT 03637205) and EURO‐SHOCK (Testing the Value of Novel Strategy and its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock, CT 03813134) trials.